| Autor: |
Tagariello G; Haemophilia Centre and Blood Bank, Centre for Blood Diseases, Castelfranco Veneto Hospital (TV), ULSS 8, Regione Veneto, Italy. tagariello@ulssasolo.ven.it, Davoli PG, Gajo GB, De Biasi E, Risato R, Baggio R, Traldi A |
| Jazyk: |
angličtina |
| Zdroj: |
Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 1999 Nov; Vol. 5 (6), pp. 426-30. |
| DOI: |
10.1046/j.1365-2516.1999.00335.x |
| Abstrakt: |
In this study we explore the feasibility of high-purity double-inactivated concentrates by continuous infusion for the treatment of haemophiliacs in a group of patients undergoing different surgical procedures. The patients were enrolled in the study on the basis of their transfusion history, which was well known due to their long-term follow up at our Haemophilia Center. We did not perform a pre-operative pharmacokinetic study because one of the aims of this study was to demonstrate that continuous infusion can become a first choice standard treatment in patients with haemophilia. Fourteen haemophilia A and one haemophilia B patients who needed at least 5 days of replacement therapy were monitored for haemostatic efficacy, post-operative factor VIII and factor IX levels and evaluated for safety and flexibility of the products. The infusion rate of 3 IU kg-1 h-1 was demonstrated to be sufficient to ensure haemostasis and patients did not need additional bolus infusion during the post-operative period. Our study demonstrates the safety and feasibility of high-purity concentrates in patients undergoing surgery by continuous infusion, also in the absence of a previous pharmacokinetic study. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
